tbuckley/cabot-search huggingface dataset:
AB0174 Urinary excretion of type 1 collagen crosslinked n-telopeptides in rheumatoid arthritis: correlation with bone mineral density
Authors: M Miyata, J Yahata, I Takizawa, Y Koike
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> A immunoassay for measuring urinary excretion of Type 1 collagen crosslinked N-Telopeptides (NTX) has been reported to be specific method for assessing bone resorption. <h3>Objectives</h3> The aim of this study was to find out the value of urinary NTX as a marker of bone atrophy in RA. <h3>Methods</h3> The study population consisted of 80 female patients with RA according to ARA criteria (1987), 42–74 years of age. We measured bone mineral density (BMD) in the radius and lumbar spine by dual energy X-ray absorptiometry in patients with RA. Using enzyme-linked immunoassays, the concentrations of urinary NTX was estimated in urine samples from RA patients. A correlation between urinary NTx and BMD of RA patients was analysed. <h3>Results</h3> In RA patients there were significant correlations between urinary NTX and BMD. <h3>Conclusion</h3> This findings suggest that urinary NTX is the useful marker of bone atrophy in RA.
Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity
Authors: Yann Cheli, Meri K. Tulic, Najla El Hachem, Nicolas Nottet, Arnaud Jacquel, Maeva Gesson, Thomas Strub, Karine Bille, Alexandra Picard-Gauci, Henri Montaudié, Guillaume E. Beranger, Thierry Passeron, Pierre Close, Corine Bertolotto, Robert Ballotti
Journal: Molecular Cancer (2021)

An amendment to this paper has been published and can be accessed via the original article.
Chronic pulmonary aspergillosis: prevalence, favouring pulmonary diseases and prognosis
Authors: Thomas Maitre, Jonathan Cottenet, Cendrine Godet, Adrien Roussot, Nafiz Abdoul Carime, Vichita Ok, Antoine Parrot, Philippe Bonniaud, Catherine Quantin, Jacques Cadranel
Journal: European Respiratory Journal (2021)

Chronic pulmonary aspergillosis (CPA) is an emerging disease in patients with common chronic pulmonary diseases (CPDs). While its prevalence is linked to tuberculosis (TB) in endemic countries, epidemiological and prognostic data are lacking in low TB incidence countries. The aim of this study was to describe these features in CPA patients hospitalised in France between 2009 and 2018.We estimated the prevalence and mortality of hospitalised CPA patients using the French nationwide administrative hospital database. We also assessed the association with CPD, thoracic interventions and malnutrition.From 2009 to 2018, 17 290 patients were hospitalised in France for CPA, with an increasing prevalence during this period. Most patients were male (63.5%) with a median age of 65 years at CPA diagnosis, living in farming regions and large cities. The proportion of underlying chronic obstructive pulmonary disease (COPD) and emphysema during the previous 5 years was 44% and 22%, respectively, whereas it was only 3% for both TB and non-TB mycobacterial (NTM) infections. The mortality rates during the first hospitalisation, at 1 year and at 5 years were 17%, 32% and 45%, respectively. In multivariate analysis, mortality rates were increased in patients aged >65 years, male patients and patients with malnutrition, diabetes or lung cancer history. The risk of mortality in patients with COPD or emphysema was higher than in those with previous mycobacterial lung infection.In France, CPA is an emerging infection commonly associated with non-mycobacterial CPD. This shift in the distribution profile of underlying CPD will likely worsen CPA mortality.
Tetracyclines promote survival and fitness in mitochondrial disease models
Authors: Elizabeth A. Perry, Christopher F. Bennett, Chi Luo, Eduardo Balsa, Mark Jedrychowski, Katherine E. O’Malley, Pedro Latorre-Muro, Richard Porter Ladley, Kamar Reda, Peter M. Wright, Steven P. Gygi, Andrew G. Myers, Pere Puigserver
Journal: Nature Metabolism (2021)
CPSF1 Regulates AML1-ETO Fusion Gene Polyadenylation and Stability in t(8;21) Acute Myelogenous Leukemia
Authors: Takahiro Shima, Amanda G Davis, Sayuri Miyauchi, Yu Kochi, Daniel T Johnson, Samuel A Stoner, Yuda Junichiro, Toshihiro Miyamoto, Jie-Hua Zhou, Edward D Ball, Koichi Akashi, Dong-Er Zhang
Journal: Blood (2017)
Impact of age on outcomes and symptoms in patients with advanced gastroesophageal cancer (GEC).
Authors: Fahad Almugbel, Laith Al-Showbaki, Husam Alqaisi, Chihiro Suzuki, Osvaldo Espin-Garcia, Marta Honório, Raymond Woo-Jun Jang, Shabbir M.H. Alibhai, Elena Elimova
Journal: Journal of Clinical Oncology (2021)

193 Background: Although age is a non-modifiable risk factor for most cancers, alone it is not very helpful in deciding on the best treatment for patients. Insufficient data exist in the oldest old ( &gt; 75 years) compared to young-old (65-75 years) and to younger ( &lt; 65 years) patients with de novo metastatic GEC regarding which factors influence response and outcomes. Methods: We retrospectively assessed all patients with de novo metastatic GEC seen from 2006-2015 at the Princess Margaret Cancer Center in Toronto-Ontario, Canada. We used Kaplan-Meier plots and Cox proportional hazards analyses to examine factors associated with progression-free survival (PFS) and overall survival (OS). To examine patient-reported outcomes we used the Edmonton Symptom Assessment System (ESAS) in the first six months of therapy using cross-sectional and longitudinal analyses. Results: A total of 580 de novo metastatic GEC patients were seen between 2006 and 2015. Of these (14%) were oldest old, (31%) were young-old (age 65-75) and 54% were younger ( &lt; 65 years). Most patients (67-80%) were male. Median OS for the entire cohort was 9.1 mo. (95% confidence interval (CI) 8.0 – 10.1); the shortest OS was in the oldest old group at 4.5 mo. compared to 8.7 mo. in young-old and 9.8 mo. in younger group, p &lt; 0.001. PFS was also significantly different among the age groups (4.4 mo., 6.1 mo., and 6.5 mo., respectively), p = 0.0145. In a multivariate model predictors for OS were age (young-old group), number of metastasis, and Eastern Cooperative Oncology Group (ECOG) performance scale (PS). Similar predictors were found for PFS; however, age was not a significant factor. Of the 55 patients who provided ESAS data, 58% were &lt; 65 and 42% were age≥ 65. The most common symptoms at presentation were fatigue, appetite, and well-being. There were no differences by age group (all p &gt; 0.05). Conclusions: Patients age &gt; 75 have poorer OS compared to younger age groups but PFS does not differ, suggesting similar benefits with treatment in appropriately selected older adults with advanced GEC. Symptom profiles were similar with age. Further comprehensive care is needed for older patients with advanced GEC to improve their survival.
Social Deprivation and Incident Diabetes-Related Foot Disease in Patients With Type 2 Diabetes: A Population-Based Cohort Study
Authors: Jenny Riley, Christina Antza, Punith Kempegowda, Anuradhaa Subramanian, Joht Singh Chandan, Krishna Gokhale, Neil Thomas, Christopher Sainsbury, Abd A. Tahrani, Krishnarajah Nirantharakumar
Journal: Diabetes Care (2021)

OBJECTIVE To investigate the relationship between social deprivation and incident diabetes-related foot disease (DFD) in newly diagnosed patients with type 2 diabetes. RESEARCH DESIGN AND METHODS A population-based open retrospective cohort study using The Health Improvement Network (1 January 2005 to 31 December 2019) was conducted. Patients with type 2 diabetes free of DFD at baseline were stratified by Townsend deprivation index, and risk of developing DFD was calculated. DFD was defined as a composite of foot ulcer (FU), Charcot arthropathy, lower-limb amputation (LLA), peripheral neuropathy (PN), peripheral vascular disease (PVD), and gangrene. RESULTS A total of 176,359 patients were eligible (56% men; mean age 62.9 [SD 13.1] years). After excluding 26,094 patients with DFD before/within 15 months of type 2 diabetes diagnosis, DFD incidentally developed in 12.1% of the study population over 3.27 years (interquartile range 1.41–5.96). Patients in the most deprived Townsend quintile had increased risk of DFD compared with those in the least deprived (adjusted hazard ratio [aHR] 1.22; 95% CI 1.16–1.29) after adjusting for sex, age at type 2 diabetes diagnosis, ethnicity, smoking, BMI, HbA1c, cardiovascular disease, hypertension, retinopathy, estimated glomerular filtration rate, insulin, glucose/lipid-lowering medication, and baseline foot risk. Patients in the most deprived Townsend quintile had higher risk of PN (aHR 1.18; 95% CI 1.11–1.25), FU (aHR 1.44; 95% CI 1.17–1.77), PVD (aHR 1.40; 95% CI 1.28–1.53), LLA (aHR 1.75; 95% CI 1.08–2.83), and gangrene (aHR 8.49; 95% CI 1.01–71.58) compared with those in the least. CONCLUSIONS Social deprivation is an independent risk factor for the development of DFD, PN, FU, PVD, LLA, and gangrene in newly diagnosed patients with type 2 diabetes. Considering the high individual and economic burdens of DFD, strategies targeting patients in socially deprived areas are needed to reduce health inequalities.
Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.
Authors: Funda Meric-Bernstam, Erika P. Hamilton, Muralidhar Beeram, Diana L. Hanna, Anthony B. El-Khoueiry, Yoon-Koo Kang, Keun Wook Lee, Jeeyun Lee, Sun Young Rha, Jorge M Chaves, Do-Youn Oh, Rachel Anne Goodwin, Jaffer A. Ajani, Todd Gray, Joseph Woolery, Elena Elimova
Journal: Journal of Clinical Oncology (2021)

164 Background: For patients with human epidermal growth factor receptor 2 (HER2)-overexpressing GEA, trastuzumab in combination with chemotherapy is the only approved HER2-targeted therapy, and they have limited treatment options after progression. Zanidatamab, a HER2-targeted bispecific antibody, has shown durable anti-tumor activity with good tolerability in a range of HER2-expressing cancers. Methods: In this 3-part Phase 1 study (NCT02892123), zanidatamab (10 mg/kg QW, 20 mg/kg Q2W, or 30 mg/kg Q3W) is administered as a single agent (Parts 1 &amp; 2; QW or Q2W) or in combination with chemotherapy (Part 3; Q2W or Q3W). Eligibility criteria includes GEA with HER2 expression as assessed by immunohistochemistry (IHC) 3+ or IHC 2+, progression after standard of care therapy, and measurable disease per RECIST 1.1 (Part 2 requirement only). Results: In Parts 1 and 2, 36 GEA patients have been treated with zanidatamab (QW [n = 5]; Q2W [n = 31]). In Part 3, 26 GEA patients have been treated (zanidatamab Q2W + (paclitaxel [n = 11] or capecitabine [n = 6]); zanidatamab Q3W + capecitabine [n = 9]). Conclusions: Zanidatamab, both as a single agent and in combination with chemotherapy, is well tolerated with promising and durable anti-tumor activity in heavily pretreated GEA patients (including prior HER2-targeted therapy). These data support further investigation of zanidatamab as a novel therapeutic for patients with HER2-expressing GEA. Clinical trial information: NCT02892123. [Table: see text]
Pros and Cons in Using Population-Based Registers for Assessing the Fetal Safety of Drugs
Authors: Stefania Triunfo, Alessandro Ceschi
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Sexual Orientation and Mental Health
Authors: Gregory M. Herek, Linda D. Garnets
Journal: Annual Review of Clinical Psychology (2007)

This article provides an overview of current psychological research on mental health and sexual orientation, as well as clinical practice with sexual minorities. The historical context for current research questions and controversies is described, and the findings of recent empirical research on psychological well-being and distress among nonheterosexuals are summarized. The minority stress model is used to frame a discussion of stressors unique to sexual minorities and to consider their possible effects on psychological well-being. The possible ameliorative effects of adopting a sexual orientation identity are examined, followed by a discussion of how these ideas translate into contemporary clinical work with sexual minority clients. The review concludes with a brief discussion of priority areas for empirical research and clinical practice.
Preliminary safety analysis of phase II open-label NIVACOR trial (GOIRC-03-2018) in patients with advanced colorectal cancer RAS or BRAF mutated.
Authors: Angela Damato, Annalisa Berselli, Francesco Iachetta, Alessandra Romagnani, Mario Larocca, Alicia Garcia Arias, Lorenzo Antonuzzo, Guglielmo Nasti, Francesca Bergamo, Carmine Pinto
Journal: Journal of Clinical Oncology (2021)

37 Background: NIVACOR trial is an open-label, multicentric Italian phase II trial of FOLFOXIRI/bevacizumab in association with an anti-PD1 antibody, nivolumab, in patients (pts) with metastatic colorectal cancer (mCRC). We report preliminary safety analysis by an Independent Monitoring Committee. Methods: Pts with mCRC RAS or BRAF mutated, regardless microsatellite status and eligible to receive a first line treatment will be enrolled. FOLFOXIRI/bevacizumab (BEV) in association with nivolumab (NIV) was administered every 2 weeks for 8 cycles (induction) followed by BEV plus NIV every 2 weeks (maintenance) until PD or unacceptable toxicities. BEV was administered intravenously at dose of 5 mg/kg and NIV intravenously as a flat dose of 240 mg every 2 weeks. The primary endpoint was the ORR. The safety is assessed after the inclusion of the 10 th patient, receiving ≥1 dose. Results: As of September 20, 2020, 25/70 pts are enrolled. The first 10 pts were evaluated for preliminary safety analysis. Median age was 58 years (32-66), 60% of pts were male, median cycles of treatment was 5.5 (1-9). 100% were KRAS G12D mut and BRAF wild type, respectively, and 2% MSI-H/dMMR. 7/10 pts experienced at least one AE related to FOLFOXIRI/BEV and 2/10 related to NIV. The most frequent grade 1-2 AEs related to FOLFOXIRI/BEV were nausea and vomiting 4(57%), fatigue 5(71%), and diarrhea 5(71%); 3(43%) pts had grade 3-4 neutropenia, and 1(14%) febrile neutropenia. Only 2 pts developed grade 1-2 AEs related to NIV represented by rash (50%) and salivary gland infection (50%); no grade 3-4 was reported. One of pts with dose delay because of serious AES (proteinuria) BEV related, and one patient discontinued due to serious AEs (ileo-urethral fistula) not related to NIV. Conclusions: Combination of FOLFOXIRI/BEV and NIV was generally well tolerated and showed an acceptable toxicity profile. The final analysis will be scheduled at the end of enrollment. Clinical trial information: NCT04072198.
Ara h 2–specific IgE is superior to whole peanut extract–based serology or skin prick test for diagnosis of peanut allergy in infancy
Authors: Corinne Keet, Mihaela Plesa, Daria Szelag, Wayne Shreffler, Robert Wood, Joan Dunlop, Roger Peng, Jennifer Dantzer, Robert G. Hamilton, Alkis Togias, Michael Pistiner
Journal: Journal of Allergy and Clinical Immunology (2021)
A Survey on State-of-the-Art Denoising Techniques for Brain Magnetic Resonance Images
Authors: Pranaba K. Mishro, Sanjay Agrawal, Rutuparna Panda, Ajith Abraham
Journal: IEEE Reviews in Biomedical Engineering (2021)

The accuracy of the magnetic resonance (MR) image diagnosis depends on the quality of the image, which degrades mainly due to noise and artifacts. The noise is introduced because of erroneous imaging environment or distortion in the transmission system. Therefore, denoising methods play an important role in enhancing the image quality. However, a tradeoff between denoising and preserving the structural details is required. Most of the existing surveys are conducted on a specific MR image modality or on limited denoising schemes. In this context, a comprehensive review on different MR image denoising techniques is inevitable. This survey suggests a new direction in categorizing the MR image denoising techniques. The categorization of the different image models used in medical image processing serves as the basis of our classification. This study includes recent improvements on deep learning-based denoising methods alongwith important traditional MR image denoising methods. The major challenges and their scope of improvement are also discussed. Further, many more evaluation indices are considered for a fair comparison. An elaborate discussion on selecting appropriate method and evaluation metric as per the kind of data is presented. This study may encourage researchers for further work in this domain.
A phase II study of infigratinib in previously treated advanced/metastatic cholangiocarcinoma with <i>FGFR</i> gene fusions/alterations.
Authors: Milind M. Javle, Robin Kate Kelley, Christoph Springfeld, Ghassan K. Abou-Alfa, Teresa Macarulla, Suebpong Tanasanvimon, Lipika Goyal, Ivan Borbath, Michael Bitzer, Wei-Peng Yong, Philip Agop Philip, Rafael Alvarez-Gallego, Amit Pande, Stacie Peacock Shepherd, Jacki Fontaine, Sameek Roychowdhury
Journal: Journal of Clinical Oncology (2021)

TPS356 Background: The FGFR family plays an important role in cholangiocarcinoma, with FGFR2 gene fusions detected in about 15% of patients with cholangiocarcinoma. Infigratinib is an FGFR1–3-selective oral tyrosine kinase inhibitor under evaluation in multiple indications including front-line and pre-treated cholangiocarcinoma. CBGJ398X2204 is an ongoing phase II study evaluating the efficacy of single-agent infigratinib in patients with advanced or metastatic cholangiocarcinoma with FGFR genetic alterations who have received prior gemcitabine. Methods: Study CBGJ398X2204 consists of 3 cohorts and patients in all cohorts receive oral infigratinib once daily for 21 days of a 28-day treatment cycle. Treatment will continue until progressive disease, intolerance, withdrawal of consent, or death. Cohort 1 includes patients with FGFR2 gene fusions or translocations. Cohort 2 includes patients with FGFR genetic alterations other than FGFR2 gene fusions (patients in both Cohorts 1 and 2 must not have received any prior FGFR inhibitors). Cohort 3 includes patients with FGFR2 gene fusions who have received prior treatment with a selective FGFR inhibitor other than infigratinib. The primary endpoint is objective response rate (ORR, RECIST v1.1 per central review). Secondary endpoints include overall survival and overall response rate (per investigator). Safety, pharmacokinetics, and exploratory genetic alterations/biomarkers will also be measured. The study was initiated in 2014 and has a planned enrollment of up to 160 patients across all 3 cohorts (120 in Cohort 1, 20 in Cohort 2, and 20 in Cohort 3). Cohort 1 has completed enrollment and findings from this Cohort are the focus of a separate abstract submitted to the meeting. Results are not currently available from Cohorts 2 and 3 (trial in progress). Clinical trial information: NCT02150967.
AB0095 Intravenous immunoglobulin in limited polyarteritis nodosa
Authors: A Balbir-Gurman, D Schapira, B Smolin, E Volfovitz, AM Nahir
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Polyarteritis nodosa (PAN) is severe systemic vasculitis that may affect almost all systems. Rarely isolated organ involvement occurs. These cases generally have more benign course and respond well to high dose of steroids. The addition of cytotoxic drugs is controversial. PAN limited to calf muscles is extremely uncommon. Painful tenderness and swelling of dorsal calf muscles, mild fever and general signs of inflammation in blood tests are the only features of this form of vasculitis. ANCA is not obligatory positive. Muscle biopsy is the only way to make the diagnosis. <h3>Objectives</h3> <h3>Methods</h3> <h3>Results</h3> <h3>Conclusion</h3> The two herein reported cases (Table 1) of biopsy proven PAN of the calve show that the addition of single course of intravenous immunoglobulin to steroid treatment yielded rapid and stable clinical and laboratory remission with low doses of steroids from the beginning and rapid tapering off.
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Authors: Jeffrey Sum Lung Wong, Gin Wai Kwok, Vikki Tang, Bryan Li, Roland Ching-Yu Leung, Joanne Wing Yan Chiu, Ka Wing Ma, Wong-Hoi She, Wing Yan Josephine Tsang, Tan To Cheung, Thomas Yau
Journal: Journal of Clinical Oncology (2021)

330 Background: Programmed cell death protein 1 (PD-1) pathway blockade with immune checkpoint inhibitors (ICI) is a standard therapy in advanced hepatocellular carcinoma (HCC) nowadays. No strategies to overcome ICI resistance have been described. We aimed to evaluate the use of ipilimumab and anti-PD-1 ICIs (nivolumab or pembrolizumab) combinations in advanced HCC patients with progression on prior ICIs. Methods: Advanced HCC patients with documented tumour progression on prior ICIs and subsequently received ipilimumab with nivolumab/pembrolizumab were analysed. Objective response rate (ORR), median duration of response (DOR), time-to-progression (TTP), overall survival (OS), and treatment-related adverse events (TRAEs) were assessed. Results: Twenty-five patients were included. The median age was 62 (range 51-83). 68% were of Child-Pugh (CP) grade A and 48% had primary resistance to prior ICI. At median follow-up of 37.7 months, the ORR was 16% with a median DOR of 11.5 months (range 2.76-30.3). Three patients achieved complete response. The median TTP was 2.96 months (95% C.I. 1.61-4.31). Median OS was 10.9 months (95% C.I. 3.99-17.8) and the 1-year, 2-year and 3-year survival rates were 42.4%, 32.3% and 21.6% respectively. The ORR was 16.7% in primary resistance group and 15.4% in acquired resistance group (p=1.00). All responders were of CP A and Albumin-Bilirubin (ALBI) grade 1 or 2. CP and ALBI grades were significantly associated with OS (p=0.006 and p&lt;0.001 respectively). Overall, 52% of patients experienced TRAEs and 12% experienced grade 3 or above TRAEs. Conclusions: Ipilimumab and nivolumab/pembrolizumab can achieve durable antitumour activity and encouraging survival outcomes with acceptable toxicity in patients with advanced HCC who had prior treatment with ICIs.